Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Should You Invest in Teva Pharmaceutical (TEVA), Here’s What the Street Has to Say
Should You Invest in Teva Pharmaceutical (TEVA), Here’s What the Street Has to Say
Talha Qureshi
Wed, February 18, 2026 at 2:56 AM GMT+9 2 min read
In this article:
TEVA
+0.49%
TEVJF
+30.47%
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the Best Performing Foreign Stocks to Buy Now. Wall Street is bullish on Teva Pharmaceutical since its fiscal Q4 2025 earnings were released on January 28.
Recently, on February 10, Goldman Sachs analyst Matthew Dellatorre reiterated a Buy rating on the stock and raised the price target from $36 to $45. Earlier on January 28, Trust Financial also raised its price target from $36 to $38, while maintaining a Buy rating on the stock.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted strong results in fiscal Q4 2025, topping Wall Street’s revenue and EPS estimates. The revenue for the quarter grew 11.4% year-over-year to $4.71 billion and surpassed estimates by $385.8 million. Moreover, the EPS of $0.92 also topped estimates by $0.32.
Management attributed the performance to growth across its key innovative brands, including AUSTEDO, AJOVY, and UZEDY. Fiscal Q4 2025 marked the first quarter where these brands collectively delivered more than $1 billion in revenue.
Analysts at Truist see the company at an early stage of expansion, with pipeline highlights including an FDA decision on Olanzapine LAI, potentially yielding a $3 billion peak sales opportunity in schizophrenia treatments.
In addition, Matthew Dellatorre of Goldman highlighted that the share price of TEVA has surged over the past year (gaining more than 105%). This improvement is driven by resolution of key challenges and improved execution across the company’s portfolio. Dellatorre added that although the stock trades above its historical multiple, the valuation remains attractive driven by improved business profile, revenue expansion, margin improvements, and debt reduction.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) develops, produces, and sells medicines. Its operations are divided into the US, Europe, and International Markets geographical segments. Each business segment covers the entire product portfolio in that region, including specialty, generics, and over-the-counter (OTC) products.
While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Terms and Privacy Policy
Privacy Dashboard
More Info